BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33:455-463. [PMID: 11172349 DOI: 10.1053/jhep.2001.21905] [Cited by in Crossref: 221] [Cited by in F6Publishing: 212] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Radkowski M, Laskus T. Persistence of hepatitis C virus after successful treatment of chronic hepatitis C: Is hepatitis C infection for life? Liver Transpl 2005;11:114-6. [DOI: 10.1002/lt.20335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther 2009;29:589-601. [PMID: 19053983 DOI: 10.1111/j.1365-2036.2008.03908.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
3 Emam M, Radwan MI, Refaey MM, Shaheen NE, Abd-elmoez S, Gerges MA. Prevalence of hepatitis C virus in an elderly population in rural areas of Sharkia governorate, Egypt: . Egyptian Liver Journal 2015;5:29-33. [DOI: 10.1097/01.elx.0000463678.53334.c7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Bhattacharya PK, Mukherjee S. Natural history of liver fibrosis progression in patients confected with hepatitis c virus and human immunodeficiency virus type 1. Rev Soc Bras Med Trop 2016;49:803-5. [DOI: 10.1590/0037-8682-0402-2015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Sharma NK, Sherker AH. Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 33-70. [DOI: 10.1007/978-1-59745-565-7_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kamitsukasa H, Harada H, Tanaka H, Yagura M, Tokita H, Ohbayashi A. Late liver-related mortality from complications of transfusion-acquired hepatitis C. Hepatology 2005;41:819-25. [DOI: 10.1002/hep.20648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Delahooke TE. Hepatitis C: What is the nature of the problem? J Viral Hepat 2004;11 Suppl 1:5-11. [PMID: 15357857 DOI: 10.1111/j.1365-2893.2004.00569.x] [Reference Citation Analysis]
8 Herrero-martínez E, Sabin CA, Lee CA, Jones IM, Pillay D, Emery VC. The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response: Antiretroviral Therapy and Anti-HCV Humoral Immunity. J Med Virol 2004;72:187-93. [DOI: 10.1002/jmv.10578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
9 Everhart JE. Alcohol and Hepatitis C: Do We Have a Drinking Problem? Gastroenterology 2006;130:1912-4. [DOI: 10.1053/j.gastro.2006.03.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
10 Koretz RL. Considerations of Study Design. Nutr Clin Pract 2017;22:593-8. [DOI: 10.1177/0115426507022006593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52:1168-1176. [PMID: 17357838 DOI: 10.1007/s10620-006-9579-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
12 Bhattacharjee D, Mukherjee K, Chakroborti G, Ghosh R, Mandal N, Bose M. Correlation Study Between HCV Genotypes Distribution Pattern and Viral Load in a Tertiary Care Hospital in Kolkata, India. J Clin Diagn Res 2015;9:DC15-7. [PMID: 26155478 DOI: 10.7860/JCDR/2015/12701.5977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev 2003;16:546-68. [PMID: 12857782 DOI: 10.1128/CMR.16.3.546-568.2003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
14 González V, Padilla E, Diago M, Giménez MD, Solà R, Matas L, Montoliu S, Morillas RM, Pérez C, Planas R. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. J Viral Hepat 2005;12:481-7. [PMID: 16108762 DOI: 10.1111/j.1365-2893.2005.00628.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kiser JJ. Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice 2009;22:405-18. [DOI: 10.1177/0897190008328695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Wiese M, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol. 2005;43:590-598. [PMID: 16237783 DOI: 10.1016/j.jhep.2005.04.007] [Cited by in Crossref: 130] [Cited by in F6Publishing: 122] [Article Influence: 8.1] [Reference Citation Analysis]
17 Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007;56:1098-1104. [PMID: 17344277 DOI: 10.1136/gut.2006.113217] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
18 Wiesner RH. Is there disease progression in patients who are hepatitis C virus antibody-positive and hepatitis C virus RNA-seronegative? Hepatology 2008;48:1734-6. [DOI: 10.1002/hep.22728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion 2006;46:695-702. [DOI: 10.1111/j.1537-2995.2006.00787.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
20 Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106-114. [PMID: 15619235 DOI: 10.1002/hep.20518] [Cited by in Crossref: 225] [Cited by in F6Publishing: 216] [Article Influence: 14.1] [Reference Citation Analysis]
21 Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002;11:515-28. [PMID: 11922860 DOI: 10.1517/13543784.11.4.515] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
22 Sterling RK, Brown RS, Hofmann CM, Luketic VA, Stravitz RT, Sanyal AJ, Contos MJ, Mills AS, Smith V, Shiffman ML. The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV. Am J Gastroenterology 2005;100:313-21. [DOI: 10.1111/j.1572-0241.2005.40116.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
23 Selvarajah S, Keating S, Heitman J, Lu K, Simmons G, Norris PJ, Operskalski E, Mosley JW, Busch MP. Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. J Gen Virol 2012;93:1673-9. [PMID: 22535775 DOI: 10.1099/vir.0.041277-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
24 Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008;134:1699-714. [DOI: 10.1053/j.gastro.2008.02.069] [Cited by in Crossref: 152] [Cited by in F6Publishing: 127] [Article Influence: 11.7] [Reference Citation Analysis]
25 Besheer T, El-Bendary M, Elalfy H, Abd El-Maksoud M, Salah M, Zalata K, Elkashef W, Elshahawy H, Raafat D, Elemshaty W, Almashad N, Zaghloul H, El-Gilany AH, Abdel Razek AA, Abd Elwahab M. Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors. J Interferon Cytokine Res. 2017;37:97-102. [PMID: 28068153 DOI: 10.1089/jir.2016.0111] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
26 Jansen PL. Liver disease in the elderly. Best Pract Res Clin Gastroenterol. 2002;16:149-158. [PMID: 11977934 DOI: 10.1053/bega.2002.0271] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
27 Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Dore GJ, Tyndall MW. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18:32-41. [PMID: 20196806 DOI: 10.1111/j.1365-2893.2010.01279.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
28 Carreño V, Bartolomé J, Castillo I, Quiroga JA. Does occult hepatitis C virus infection exist? J Clin Microbiol 2008;46:3550; author reply 3550-2. [PMID: 18836065 DOI: 10.1128/JCM.01148-08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474-1482. [PMID: 18008226 DOI: 10.1086/522608] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 9.2] [Reference Citation Analysis]
30 Anders RA, Yerian LM, Tretiakova M, Davison JM, Quigg RJ, Domer PH, Hoberg J, Hart J. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol. 2003;162:991-1000. [PMID: 12598331 DOI: 10.1016/s0002-9440(10)63893-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
31 Just SA, Grau K, Georgsen J, Weis N, Cowan S, Groenbaek K, Krarup H, Christensen PB; The Danish HCV Lookback Group. Long-term follow-up among Danish transfusion recipients identified in the national hepatitis C lookback: DANISH HEPATITIS C LOOKBACK FOLLOW-UP. Transfusion 2012;52:582-8. [DOI: 10.1111/j.1537-2995.2011.03309.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Maor Y, Morali G, Bashari D, Pénaranda G, Schapiro JM, Martinowitz U, Halfon P. Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel. Haemophilia 2013;19:150-6. [PMID: 22913807 DOI: 10.1111/j.1365-2516.2012.02932.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
33 Hofer H, Neufeld JB, Oesterreicher C, Grundtner P, Wrba F, Gangl A, Ferenci P, Gasche C. Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes Immun 2005;6:242-7. [PMID: 15729365 DOI: 10.1038/sj.gene.6364168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
34 Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004;112:1075-80. [PMID: 15386355 DOI: 10.1002/ijc.20507] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
35 Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon Monotherapy for Dialysis Patients With Chronic Hepatitis C: An Analysis of The Literature on Efficacy and Safety. American Journal of Gastroenterology 2003;98:1610-5. [DOI: 10.1111/j.1572-0241.2003.07526.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
36 Hassoun Z, Gores GJ. What surgeons should know about viral hepatitis and hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:1-11. [PMID: 12735125 DOI: 10.1016/S1055-3207(02)00081-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
38 Kondili LA, Chionne P, Costantino A, Villano U, Lo Noce C, Pannozzo F, Mele A, Giampaoli S, Rapicetta M. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut. 2002;50:693-696. [PMID: 11950818 DOI: 10.1136/gut.50.5.693] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 3.8] [Reference Citation Analysis]
39 Rao HY, Sun DG, Yang RF, Liu F, Wang J, Feng B, Wu N, Fang JL, Song GJ, Ma H. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol. 2012;27:526-532. [PMID: 21871021 DOI: 10.1111/j.1440-1746.2011.06880.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
40 Maor Y, Bashari D, Kenet G, Lalezari S, Lubetsky A, Luboshitz J, Schapiro JM, Avidan B, Bar-meir S, Martinowitz U. Hepatitis C at the Israeli National Hemophilia Center. Haemophilia 2006;12:68-74. [DOI: 10.1111/j.1365-2516.2006.01178.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
41 McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, Hennessy TW, Williams J, Sullivan D, Rosen HR, Gretch D. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology 2010; 138: 922-31. e1. [PMID: 19909749 DOI: 10.1053/j.gastro.2009.10.056] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
42 Narciso-Schiavon JL, Schiavon LL, Carvalho-Filho RJ, Freire FC, Cardoso JR, Bordin JO, Silva AE, Ferraz ML. Anti-hepatitis C virus-positive blood donors: are women any different? Transfus Med. 2008;18:175-183. [PMID: 18598280 DOI: 10.1111/j.1365-3148.2008.00859.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
43 Eyster ME, Sanders J, Goedert JJ. Viral clearance occurs very early during the natural resolution of hepatitis C virus infection in persons with haemophilia. Haemophilia 2004;10:75-80. [DOI: 10.1046/j.1351-8216.2003.00836.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
44 Wang XH, Netski DM, Astemborski J, Mehta SH, Torbenson MS, Thomas DL, Ray SC. Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution. J Virol 2007;81:6513-22. [PMID: 17329332 DOI: 10.1128/JVI.02276-06] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
45 Tobler LH, Stramer SL, Lee SR, Masecar BL, Peterson JE, Davis EA, Andrews WE, Brodsky JP, Kleinman SH, Phelps BH, Busch MP. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening: IMPACT OF HCV 3.0 EIA ON VOLUNTEER DONOR SCREENING. Transfusion 2003;43:1452-9. [DOI: 10.1046/j.1537-2995.2003.00521.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
46 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1053/jhep.2002.36227] [Cited by in Crossref: 94] [Cited by in F6Publishing: 362] [Article Influence: 4.9] [Reference Citation Analysis]
47 Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406-3417. [PMID: 19188662 DOI: 10.1182/blood-2008-10-167643] [Cited by in Crossref: 376] [Cited by in F6Publishing: 325] [Article Influence: 31.3] [Reference Citation Analysis]
48 Choi SS, Bradrick S, Qiang G, Mostafavi A, Chaturvedi G, Weinman SA, Diehl AM, Jhaveri R. Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. Hepatology. 2011;54:1580-1590. [PMID: 21793033 DOI: 10.1002/hep.24576] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
49 Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, Ramezani-Binabaj M, Miri SM, Alavian SM. Occult HCV Infection: The Current State of Knowledge. Iran Red Crescent Med J. 2015;17:e34181. [PMID: 26734487 DOI: 10.5812/ircmj.34181] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
50 Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, Goedert JJ. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood. 2006;107:892-897. [PMID: 16204310 DOI: 10.1182/blood-2005-07-2781] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 3.8] [Reference Citation Analysis]
51 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1002/hep.1840360704] [Cited by in Crossref: 382] [Cited by in F6Publishing: 233] [Article Influence: 20.1] [Reference Citation Analysis]
52 Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46 Suppl 5:S165-S173. [PMID: 25458776 DOI: 10.1016/j.dld.2014.10.005] [Cited by in Crossref: 163] [Cited by in F6Publishing: 149] [Article Influence: 23.3] [Reference Citation Analysis]
53 Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Annals of Hepatology 2008;7:114-9. [DOI: 10.1016/s1665-2681(19)31865-4] [Cited by in Crossref: 17] [Article Influence: 1.3] [Reference Citation Analysis]
54 Di Martino V, Crouzet J, Hillon P, Thévenot T, Minello A, Monnet E. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat. 2011;18:493-505. [PMID: 21692956 DOI: 10.1111/j.1365-2893.2011.01476.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
55 Nurgalieva ZZ, Hollinger FB, Graham DY, Zhangabylova S, Zhangabylov A. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. World J Gastroenterol 2007; 13(8): 1204-1207 [PMID: 17451200 DOI: 10.3748/wjg.v13.i8.1204] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
56 Lin J, Chen Y, Cheng S, Chen P, Chu H, Hsieh T, Shih Y. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan. Journal of the Formosan Medical Association 2014;113:727-33. [DOI: 10.1016/j.jfma.2013.10.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
57 High KP, Marcus E, Tur-kaspa R. Chronic Hepatitis C Virus Infection in Older Adults. Clinical Infectious Diseases 2005;41:1606-12. [DOI: 10.1086/497597] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
58 Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198:1337-1344. [PMID: 18767985 DOI: 10.1086/592171] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 8.6] [Reference Citation Analysis]
59 Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97-104. [PMID: 12512034 DOI: 10.1053/gast.2003.50018] [Cited by in Crossref: 296] [Cited by in F6Publishing: 261] [Article Influence: 16.4] [Reference Citation Analysis]
60 Dufour DR, Talastas M, Fernandez MDA, Harris B, Strader DB, Seeff LB. Low-Positive Anti-Hepatitis C Virus Enzyme Immunoassay Results: An Important Predictor of Low Likelihood of Hepatitis C Infection. Clinical Chemistry 2003;49:479-86. [DOI: 10.1373/49.3.479] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
61 Fernández Rodriguez CM, Gutierrez Garcia ML. [Impact of antiviral therapy on the natural history of hepatitis C virus]. Gastroenterol Hepatol 2014;37:583-92. [PMID: 25066318 DOI: 10.1016/j.gastrohep.2014.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M, Tsubouchi H. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009;50:393-9. [PMID: 19585614 DOI: 10.1002/hep.23002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
63 Picchio GR, Baré PC, Descalzi VI, Bussy MV, Soria SM, Raffa MP, Mazzencio NE, Etchehun S, Cámera JA, Mosier DE. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int. 2006;26:660-665. [PMID: 16842321 DOI: 10.1111/j.1478-3231.2006.01290.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tsui JI, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006;44:262-6. [PMID: 16226823 DOI: 10.1016/j.jhep.2005.07.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
65 Liu CJ, Chen PJ, Shau WY, Kao JH, Lai MY, Chen DS. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int. 2003;23:148-155. [PMID: 12955877 DOI: 10.1034/j.1600-0676.2003.00820.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
66 Monteiro MRDCC, Nascimento MMPD, Passos ADC, Figueiredo JFDC. Hepatite C: prevalência e fatores de risco entre portadores do VIH/SIDA em Belém, Pará, na Amazônia brasileira. Rev Soc Bras Med Trop 2004;37:40-6. [DOI: 10.1590/s0037-86822004000700006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
67 Gelson W, Alexander G. Is elimination of hepatitis C from the UK by 2030 a realistic goal? Br Med Bull 2017;123:59-67. [PMID: 28605444 DOI: 10.1093/bmb/ldx017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28:243-250. [PMID: 24839620 DOI: 10.1155/2014/317623] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 15.2] [Reference Citation Analysis]
69 Harris HE, Ramsay ME, Andrews NJ. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect. 2006;134:472-477. [PMID: 16255834 DOI: 10.1017/s0950268805005340] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
70 Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383-398, vi. [PMID: 16023972 DOI: 10.1016/j.cld.2005.05.003] [Cited by in Crossref: 254] [Cited by in F6Publishing: 240] [Article Influence: 15.9] [Reference Citation Analysis]
71 Tawk HM, Vickery K, Bisset L, Lo SK, Cossart YE; the Infection in Endoscopy Study Group. The significance of transfusion in the past as a risk for current hepatitis B and hepatitis C infection: a study in endoscopy patients. Transfusion 2005;45:807-13. [DOI: 10.1111/j.1537-2995.2005.04317.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
72 Thein HH, Yi Q, Heathcote EJ, Krahn MD. Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. J Viral Hepat. 2009;16:802-813. [PMID: 19413692 DOI: 10.1111/j.1365-2893.2009.01136.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology 2017;67:1134-6. [DOI: 10.1016/j.jhep.2017.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
74 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
75 Salek TP, Katz AR, Lenze SM, Lusk HM, Li D, Des Jarlais DC. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW). Int J Drug Policy 2017;48:34-43. [PMID: 28779632 DOI: 10.1016/j.drugpo.2017.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
77 Virginia Reggiardo M, Fay F, Tanno M, García-camacho G, Bottaso O, Ferretti S, Godoy A, Guerrita C, Paez M, Tanno F, Ruffinengo O, Benetti S, García Borrás SE, Celina Rossi M, Vorobioff J, Bessone F, Tanno H. Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects. Annals of Hepatology 2012;11:658-66. [DOI: 10.1016/s1665-2681(19)31439-5] [Cited by in Crossref: 13] [Article Influence: 1.4] [Reference Citation Analysis]
78 Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, Ffrench RA. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007;85:24-32. [PMID: 17130897 DOI: 10.1038/sj.icb.7100010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
79 Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Crocè LS, Granito A, Tiribelli C, Bellentani S. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008;103:2248-53. [PMID: 18637095 DOI: 10.1111/j.1572-0241.2008.01948.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
80 Persico M, Bruno S, Costantino A, Mazza M, Almasio PL. The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol 2011;2011:314301. [PMID: 22164334 DOI: 10.4061/2011/314301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Shata MT, Anthony DD, Carlson NL, Andrus L, Brotman B, Tricoche N, Mccormack P, Prince A. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 2002;9:400-10. [DOI: 10.1046/j.1365-2893.2002.00373.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
82 Roed T, Lebech AM, Kjaer A, Weis N. Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging. 2012;32:421-430. [PMID: 23031062 DOI: 10.1111/j.1475-097x.2012.01152.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
83 Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432. [PMID: 12584228 DOI: 10.1136/gut.52.3.425] [Cited by in Crossref: 147] [Cited by in F6Publishing: 139] [Article Influence: 8.2] [Reference Citation Analysis]
84 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection. Cochrane Database Syst Rev 2018;12:CD011644. [PMID: 30521693 DOI: 10.1002/14651858.CD011644.pub3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
86 Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013;:CD003617. [PMID: 23440791 DOI: 10.1002/14651858.CD003617.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
87 Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938-945. [PMID: 16962883 DOI: 10.1016/s0140-6736(06)69374-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 57] [Article Influence: 11.9] [Reference Citation Analysis]
88 Feld JJ, Liang TJ. Hepatitis C — identifying patients with progressive liver injury. Hepatology 2006;43:S194-206. [DOI: 10.1002/hep.21065] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
89 Orland JR, Wang B, Wright DJ, Nass CC, Garratty G, Smith JW, Newman B, Smith DM, Murphy EL; HOST Investigators. Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study. Retrovirology 2004;1:4. [PMID: 15169553 DOI: 10.1186/1742-4690-1-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
90 Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. Hepatology. 2005;42:86-92. [PMID: 15954090 DOI: 10.1002/hep.20742] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
91 Jafferbhoy H, Gashau W, Dillon J. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res 2010;2:87-96. [PMID: 21935317 DOI: 10.2147/ceor.s7283] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
92 Maylin S, Martinot-Peignoux M, Ripault MP, Moucari R, Cardoso AC, Boyer N, Giuily N, Castelnau C, Pouteau M, Asselah T, Nicolas-Chanoine MH, Marcellin P. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009;29:511-7. [PMID: 19076273 DOI: 10.1111/j.1478-3231.2008.01918.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
93 Ragni MV, Moore CG, Soadwa K, Nalesnik MA, Zajko AB, Cortese-Hassett A, Whiteside TL, Hart S, Zeevi A, Li J, Shaikh OS; HHH Study Group. Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia 2011;17:103-11. [PMID: 20722744 DOI: 10.1111/j.1365-2516.2010.02366.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
94 Kenny-Walsh E. Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification. Hepatology 2009;50:349-51. [PMID: 19642170 DOI: 10.1002/hep.23107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
95 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
96 Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321-32. [PMID: 18657711 DOI: 10.1016/S0140-6736(08)61116-2] [Cited by in Crossref: 177] [Cited by in F6Publishing: 66] [Article Influence: 13.6] [Reference Citation Analysis]
97 Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:924-33; quiz e117. [PMID: 20713178 DOI: 10.1016/j.cgh.2010.06.032] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
98 Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, Gangl A, Ferenci P. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60-64. [PMID: 12500189 DOI: 10.1053/jhep.2003.50019] [Cited by in Crossref: 132] [Cited by in F6Publishing: 134] [Article Influence: 7.3] [Reference Citation Analysis]
99 Myers RP, Patel K, Pianko S, Poynard T, Mchutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003;10:16-22. [DOI: 10.1046/j.1365-2893.2003.00387.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
100 El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011;53:150-7. [PMID: 21665867 DOI: 10.1093/cid/cir306] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 9.6] [Reference Citation Analysis]
101 Messick K, Sanders JC, Goedert JJ, Eyster ME. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia 2001;7:568-74. [PMID: 11851755 DOI: 10.1046/j.1365-2516.2001.00559.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
102 Harris HE, Mieli-vergani G, Kelly D, Davison S, Gibb DM, Ramsay ME. A National Sample of Individuals Who Acquired Hepatitis C Virus Infections in Childhood or Adolescence: Risk Factors for Advanced Disease. Journal of Pediatric Gastroenterology & Nutrition 2007;45:335-41. [DOI: 10.1097/mpg.0b013e3180dc9337] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
103 Werb D, Wood E, Kerr T, Hershfield N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006–2026. International Journal of Drug Policy 2011;22:70-6. [DOI: 10.1016/j.drugpo.2010.09.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
104 Josset V, Chamouni P, Tavolacci MP, Merle V, Delbos V, Froment L, Ladner J, Ounnoughene N, Czernichow P. [Efficiency of hepatitis C virus screening before and after blood transfusion]. Transfus Clin Biol 2004;11:186-91. [PMID: 15564099 DOI: 10.1016/j.tracli.2004.09.002] [Reference Citation Analysis]
105 Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology. 2008;47:1446-1452. [PMID: 18220272 DOI: 10.1002/hep.22184] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
106 Aswad S, Khan NS, Comanor L, Chinchilla C, Corado L, Mone T, Mendez R, Mendez R. Role of nucleic acid testing in cadaver organ donor screening: detection of hepatitis C virus RNA in seropositive and seronegative donors. J Viral Hepat 2005;12:627-34. [PMID: 16255764 DOI: 10.1111/j.1365-2893.2005.00632.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
107 Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol. 2008;48:200-207. [PMID: 18086507 DOI: 10.1016/j.jhep.2007.09.010] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 8.1] [Reference Citation Analysis]
108 Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 2020;3:e204192. [PMID: 32374397 DOI: 10.1001/jamanetworkopen.2020.4192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
109 Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis. 2001;14:593-601. [PMID: 11964881 DOI: 10.1097/00001432-200110000-00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
110 Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, Mccormack P, Pfahler W, Lee D, Tobler LH, Busch M, Prince AM. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003;314:601-16. [DOI: 10.1016/s0042-6822(03)00461-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
111 Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010;43:217-23. [PMID: 20563484 DOI: 10.1590/s0037-86822010000300001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
112 Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol. 2008;103:2123-2134. [PMID: 18796105 DOI: 10.1111/j.1572-0241.2008.01981.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
113 Inoue K, Tsukiyama-Kohara K, Matsuda C, Yoneyama M, Fujita T, Kuge S, Yoshiba M, Kohara M. Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1. Biochem Biophys Res Commun. 2012;428:494-499. [PMID: 23122814 DOI: 10.1016/j.bbrc.2012.10.079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
114 Busch MP, Murthy KK, Kleinman SH, Hirschkorn DF, Herring BL, Delwart EL, Racanelli V, Yoon JC, Rehermann B, Alter HJ. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326-34. [PMID: 22498743 DOI: 10.1182/blood-2011-12-393637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
115 Luban NL, Colvin CA, Mohan P, Alter HJ. The epidemiology of transfusion-associated hepatitis C in a children's hospital. Transfusion 2007;47:615-20. [PMID: 17381619 DOI: 10.1111/j.1537-2995.2007.01162.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
116 Pereira A, Bruguera M. [Forecasting the impact of hepatitis C in Catalonia (Spain)]. Med Clin (Barc) 2002;119:377-81. [PMID: 12372170 DOI: 10.1016/s0025-7753(02)73422-2] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
117 Duberg AS, Törner A, Davidsdóttir L, Aleman S, Blaxhult A, Svensson A, Hultcrantz R, Bäck E, Ekdahl K. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008;15:538-550. [PMID: 18397223 DOI: 10.1111/j.1365-2893.2008.00982.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
118 El-attar MM, Ahmed MA, Shehata Hasan M, Aly MA, Nasr AM. Spontaneous viral clearance of chronic HCV infection in Upper Egypt: A community-based study with a 10year follow-up. Arab Journal of Gastroenterology 2010;11:197-201. [DOI: 10.1016/j.ajg.2010.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Sahakyan Y, Wong WW, Yi Q, Thein HH, Tomlinson GA, Krahn MD. Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up. J Viral Hepat 2020;27:235-42. [PMID: 31654536 DOI: 10.1111/jvh.13226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L, Cross R, Degré D. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol. 2011;55:38-44. [PMID: 21145859 DOI: 10.1016/j.jhep.2010.10.018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
121 Sugden PB, Cameron B, Bull R, White PA, Lloyd AR. Occult infection with hepatitis C virus: friend or foe? Immunol Cell Biol 2012;90:763-73. [PMID: 22546735 DOI: 10.1038/icb.2012.20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
122 Cameron B, Galbraith S, Li H, Lloyd A; the HITS investigators. Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates. J Viral Hepat 2013;20:e96-e106. [DOI: 10.1111/jvh.12016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
123 Piro L, Solinas S, Luciani M, Casale A, Bighiani T, Santonocito D, Girelli G. Prospective study of the meaning of indeterminate results of the recombinant immunoblot assay for hepatitis C virus in blood donors. Blood Transfus 2008;6:107-11. [PMID: 18946955 DOI: 10.2450/2008.0037-07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion. 2006;46:1360-1366. [PMID: 16934072 DOI: 10.1111/j.1537-2995.2006.00903.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
125 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
126 Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20(28): 9270-9280 [PMID: 25071320 DOI: 10.3748/wjg.v20.i28.9270] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
127 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-229. [PMID: 15738952 DOI: 10.1038/nri1573] [Cited by in Crossref: 1133] [Cited by in F6Publishing: 1071] [Article Influence: 70.8] [Reference Citation Analysis]
128 Omland LH, Jepsen P, Krarup H, Schønning K, Lind B, Kromann-Andersen H, Homburg KM, Christensen PB, Sørensen HT, Obel N. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol. 2011;9:71-78. [PMID: 20888437 DOI: 10.1016/j.cgh.2010.09.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
129 Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124. [PMID: 20303034 DOI: 10.1016/j.tmrv.2009.11.001] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 10.5] [Reference Citation Analysis]
130 Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, Farci P, Emerson SU, Chisari FV, Purcell RH, Bukh J. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J Virol 2007;81:7208-19. [PMID: 17409145 DOI: 10.1128/JVI.01774-06] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
131 Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol. 2003;25:184-192. [PMID: 12621235 DOI: 10.1097/00043426-200303000-00002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
132 Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-88. [PMID: 15483230 DOI: 10.1099/vir.0.80401-0] [Cited by in Crossref: 590] [Cited by in F6Publishing: 580] [Article Influence: 34.7] [Reference Citation Analysis]
133 Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, Brant L, Harris HE. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. Journal of Clinical Epidemiology 2006;59:144-52. [DOI: 10.1016/j.jclinepi.2005.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
134 Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol. 2013;58:31-37. [PMID: 22960427 DOI: 10.1016/j.jhep.2012.08.024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
135 Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-meir S, Martinowitz U, Halfon P. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006;12:372-9. [DOI: 10.1111/j.1365-2516.2006.01290.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
136 Hu D, Bower W, Ward J. Viral Hepatitis. Atlas of Sexually Transmitted Diseases and AIDS. Elsevier; 2010. pp. 203-29. [DOI: 10.1016/b978-0-7020-4060-3.00012-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
137 Laskus T, Wilkinson J, Gallegos-orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004;127:764-76. [DOI: 10.1053/j.gastro.2004.06.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
138 Omland LH, Jepsen P, Weis N, Christensen PB, Laursen AL, Nielsen H, Krarup H, Sørensen HT, Obel N. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepat 2010;17:261-8. [PMID: 19709359 DOI: 10.1111/j.1365-2893.2009.01175.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
139 Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99. [PMID: 19207971 DOI: 10.1111/j.1478-3231.2008.01927.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 151] [Article Influence: 13.4] [Reference Citation Analysis]
140 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1053/jhep.2002.36806] [Cited by in Crossref: 127] [Cited by in F6Publishing: 443] [Article Influence: 6.7] [Reference Citation Analysis]
141 Patel H, Heathcote EJ. When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia 2009;15:20-32. [DOI: 10.1111/j.1365-2516.2008.01917.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
142 Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, Dockter J, Giachetti C, Seeff LB, Busch MP; Transfusion-transmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008;15:120-8. [PMID: 18184195 DOI: 10.1111/j.1365-2893.2007.00900.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
143 Sypsa V, Touloumi G, Papatheodoridis GV, Tassopoulos NC, Ketikoglou I, Vafiadis I, Hatzis G, Tsantoulas D, Akriviadis E, Koutsounas S, Hatzakis A. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005;12:543-50. [DOI: 10.1111/j.1365-2893.2005.00588.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
144 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011644. [PMID: 28285495 DOI: 10.1002/14651858.CD011644.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Rafik M, Bakr S, Soliman D, Mohammed N, Ragab D, ElHady WA, Samir N. Characterization of differential antibody production against hepatitis C virus in different HCV infection status. Virol J 2016;13:116. [PMID: 27357382 DOI: 10.1186/s12985-016-0572-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
146 Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Alimentary Pharmacology & Therapeutics 2010;31:502-8. [DOI: 10.1111/j.1365-2036.2009.04201.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
147 Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB; DILIN Investigators. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.Am J Gastroenterol. 2015;110:1450-1459. [PMID: 26346867 DOI: 10.1038/ajg.2015.283] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 10.7] [Reference Citation Analysis]
148 Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study. J Hepatol 2014;60:260-6. [PMID: 24096048 DOI: 10.1016/j.jhep.2013.09.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
149 Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol 2005;42 Suppl:S108-14. [PMID: 15777565 DOI: 10.1016/j.jhep.2004.10.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
150 Wlcek K, Koller F, Ferenci P, Stieger B. Hepatocellular organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are inhibited by silibinin. Drug Metab Dispos 2013;41:1522-8. [PMID: 23695864 DOI: 10.1124/dmd.113.051037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
151 Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clinical Infectious Diseases 2005;40:S131-235. [DOI: 10.1086/427906] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
152 Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. Expert Rev Anti Infect Ther 2009;7:351-61. [PMID: 19344247 DOI: 10.1586/eri.09.8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
153 Hardikar W. Hepatitis C in childhood. J Gastroenterol Hepatol 2002;17:476-81. [DOI: 10.1046/j.1440-1746.2002.02731.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
154 Chionne P, Madonna E, Villano U, Tritarelli E, Pisani G, Costantino A, Equestre M, Marcantonio C, Bruni R, Ciccaglione AR. Sensitivity of hepatitis C virus rapid tests in detecting antibodies in general population. Panminerva Med 2020;62:125-30. [PMID: 31692308 DOI: 10.23736/S0031-0808.19.03678-4] [Reference Citation Analysis]
155 Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62:1396-1404. [PMID: 26126725 DOI: 10.1002/hep.27966] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
156 Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675-1684. [PMID: 17133499 DOI: 10.1002/hep.21440] [Cited by in Crossref: 117] [Cited by in F6Publishing: 96] [Article Influence: 8.4] [Reference Citation Analysis]
157 Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008;167:743-750. [PMID: 18203734 DOI: 10.1093/aje/kwm370] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 7.2] [Reference Citation Analysis]
158 Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012;206:654-61. [PMID: 22740714 DOI: 10.1093/infdis/jis410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
159 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
160 Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006;46:1624-40. [DOI: 10.1111/j.1537-2995.2006.00957.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
161 Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Addiction. 2012;107:1984-1995. [PMID: 22564041 DOI: 10.1111/j.1360-0443.2012.03932.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 12.2] [Reference Citation Analysis]
162 Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options in Oncol 2001;2:473-83. [DOI: 10.1007/s11864-001-0069-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
163 Lefrère J, Girot R, Lefrère F, Guillaume N, Lerable J, Marrec NL, Bouchardeau F, Laperche S. Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion: SEROREVERSION AF TER HCV INFECTION. Transfusion 2004;44:343-8. [DOI: 10.1111/j.1537-2995.2004.00656.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
164 Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol 2012; 18(12): 1385-1390 [PMID: 22493553 DOI: 10.3748/wjg.v18.i12.1385] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
165 Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN, Mohammad Alizadeh AH. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 2011;83:989-95. [PMID: 21503911 DOI: 10.1002/jmv.22044] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
166 Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays: RIBA-3-INDETERMINATE RESULTS IN BLOOD DONORS. Transfusion 2004;44:349-58. [DOI: 10.1111/j.1537-2995.2003.00671.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
167 Ghany M. E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. Hepatology 2003;38:1092-4. [DOI: 10.1053/jhep.2003.50499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Garvey P, Murphy N, Flanagan P, Brennan A, Courtney G, Crosbie O, Crowe J, Hegarty J, Lee J, Mciver M, Mcnulty C, Murray F, Nolan N, O'farrelly C, Stewart S, Tait M, Norris S, Thornton L. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s. Journal of Hepatology 2017;67:1140-7. [DOI: 10.1016/j.jhep.2017.07.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol 2013; 19(7): 1085-1090 [PMID: 23467073 DOI: 10.3748/wjg.v19.i7.1085] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
170 McKenna O, Cunningham C, Blake C. Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey. BMC Public Health 2009;9:323. [PMID: 19735567 DOI: 10.1186/1471-2458-9-323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
171 Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias. Am J Gastroenterol. 2003;98:2535-2542. [PMID: 14638360 DOI: 10.1111/j.1572-0241.2003.07678.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
172 Song D, Kang JE, Kim SY, Hwang SH, Kim HH, Lee EY, Son HC. Evaluation of ARCHITECT HCV core antigen assay. Korean J Lab Med. 2010;30:654-659. [PMID: 21157153 DOI: 10.3343/kjlm.2010.30.6.654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
173 Okuda K. Hepatocellular carcinoma--history, current status and perspectives. Dig Liver Dis 2002;34:613-6. [PMID: 12405244 DOI: 10.1016/s1590-8658(02)80200-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
174 Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90-96. [PMID: 14752827 DOI: 10.1002/hep.20030] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 6.5] [Reference Citation Analysis]
175 Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, Luban NL, Alter HJ. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:168-174, 174.e1. [PMID: 17236895 DOI: 10.1016/j.jpeds.2006.11.037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
176 Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein M, Dore G, Mocroft A, Soriano V, Clotet B, Lundgren J; the SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. CLIN INFECT DIS 2008;47:1468-75. [DOI: 10.1086/593102] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
177 Delwaide J, Bourgeois N, Gérard C, De Maeght S, Mokaddem F, Wain E, Bastens B, Fevery J, Géhénot M, Le Moine O, Martinet JP, Robaeys G, Servais B, Van Gossum M, Van Vlierberghe H; the Belgian Association for the Study of the Liver (BASL). Treatment of acute hepatitis C with interferon α-2b: early initiation of treatment is the most effective predictive factor of sustained viral response: TREATMENT OF ACUTE HEPATITIS C WITH INTERFERON ALPHA. Alimentary Pharmacology & Therapeutics 2004;20:15-22. [DOI: 10.1111/j.1365-2036.2004.02023.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
178 Chen JY, Chung RT. Can we use the "C" word with confidence? Cure for chronic hepatitis C. Gastroenterology 2011;140:766-8. [PMID: 21256845 DOI: 10.1053/j.gastro.2011.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
179 Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol. 2006;45:607-616. [PMID: 16901579 DOI: 10.1016/j.jhep.2006.07.003] [Cited by in Crossref: 160] [Cited by in F6Publishing: 133] [Article Influence: 10.7] [Reference Citation Analysis]
180 Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100-1108. [PMID: 21480316 DOI: 10.1002/hep.24169] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
181 Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-meir S, Martinowitz U, Halfon P. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:722-9. [DOI: 10.1111/j.1365-2516.2007.01548.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
182 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis 2004;19:351-6. [PMID: 15554427 DOI: 10.1023/b:mebr.0000043981.89134.39] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
183 Lee LM, Henderson DK. Emerging viral infections: . Current Opinion in Infectious Diseases 2001;14:467-80. [DOI: 10.1097/00001432-200108000-00012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
184 Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:183-97. [DOI: 10.1016/s1542-3565(04)00002-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
185 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis. 2004;19:351-356. [PMID: 15554427 DOI: 10.1023/b: mebr.0000043981.89134.39] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46. [PMID: 12407575 DOI: 10.1002/hep.1840360706] [Cited by in Crossref: 482] [Cited by in F6Publishing: 299] [Article Influence: 25.4] [Reference Citation Analysis]
187 Hung CH, Lu SN, Wang JH, Hung SF, Chen CH, Hu TH, Lee CM, Changchien CS. Identified cases of acute hepatitis C from computerized laboratory database: a hospital-based epidemiological and clinical study. J Infect 2008;56:274-80. [PMID: 18346790 DOI: 10.1016/j.jinf.2008.01.049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
188 Abdo AA, Sanai FM. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects. Ann Saudi Med 2009;29:1-3. [PMID: 19139625 DOI: 10.4103/0256-4947.51810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
189 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 430] [Article Influence: 30.3] [Reference Citation Analysis]
190 Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, Donato F, Zanetti AR, Podda M. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993-1000. [PMID: 12297849 DOI: 10.1053/jhep.2002.36129] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 2.8] [Reference Citation Analysis]
191 Huang RH, Hu KQ. A practical approach to managing patients with HCV infection. Int J Med Sci 2006;3:63-8. [PMID: 16614745 DOI: 10.7150/ijms.3.63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
192 Krajden M, Shivji R, Gunadasa K, Mak A, McNabb G, Friesenhahn M, Hendricks D, Comanor L. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J Clin Microbiol 2004;42:4054-9. [PMID: 15364989 DOI: 10.1128/JCM.42.9.4054-4059.2004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
193 Grady B, van den Berg C, van der Helm J, Schinkel J, Coutinho R, Krol A, Prins M. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol 2011;9:786-792.e1. [PMID: 21699803 DOI: 10.1016/j.cgh.2011.05.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
194 Shiffman ML. The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver Int 2018;38:34-9. [DOI: 10.1111/liv.13647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
195 Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion. 2009;49:176-184. [PMID: 19140810 DOI: 10.1111/j.1537-2995.2008.01961.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
196 Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Dodd RY, Kleinman SH. Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion. 2013;53:2525-2537. [PMID: 23550838 DOI: 10.1111/trf.12178] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
197 Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30. [PMID: 11982723 DOI: 10.1046/j.1440-1746.2002.02730.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
198 Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol. 2001;79:515-536. [PMID: 11903612 DOI: 10.1046/j.1440-1711.2001.01036.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.3] [Reference Citation Analysis]
199 O'Brien TR, Kirk G, Zhang M. Hepatocellular carcinoma: paradigm of preventive oncology. Cancer J. 2004;10:67-73. [PMID: 15130266 DOI: 10.1097/00130404-200403000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
200 Makuria AT, Raghuraman S, Burbelo PD, Cantilena CC, Allison RD, Gibble J, Rehermann B, Alter HJ. The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion 2012;52:1940-8. [PMID: 22304422 DOI: 10.1111/j.1537-2995.2011.03524.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
201 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 13.4] [Reference Citation Analysis]
202 Al-faleh FZ. Changing Pattern of Hepatitis Viral Infection in Saudi Arabia in the Last Two Decades. Ann Saudi Med 2003;23:367-71. [DOI: 10.5144/0256-4947.2003.367] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
203 Heller T, Seeff LB. Viral load as a predictor of progression of chronic hepatitis C? Hepatology 2005;42:1261-3. [PMID: 16317702 DOI: 10.1002/hep.20982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
204 Rauch A, Gaudieri S, Thio C, Bochud P. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009;10:1819-37. [DOI: 10.2217/pgs.09.121] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
205 Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol. 2005;43:550-552. [PMID: 16099527 DOI: 10.1016/j.jhep.2005.07.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.7] [Reference Citation Analysis]
206 Mcmahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, Deubner H, Bruce MG, Livingston S, Williams J, Gretch DR. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004;39:325-32. [DOI: 10.1002/hep.20046] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
207 Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One 2012;7:e52158. [PMID: 23284915 DOI: 10.1371/journal.pone.0052158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
208 Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18. [PMID: 18184025 DOI: 10.2165/00002512-200825010-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
209 Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631-657. [PMID: 14520615 DOI: 10.1016/s0272-6386(03)00828-x] [Cited by in Crossref: 246] [Cited by in F6Publishing: 62] [Article Influence: 14.5] [Reference Citation Analysis]
210 Sterling RK, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol. 2004;99:866-872. [PMID: 15128352 DOI: 10.1111/j.1572-0241.2004.30310.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
211 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 190] [Article Influence: 39.2] [Reference Citation Analysis]
212 Fu Y, Xia W, Wang Y, Tian L, Pybus OG, Lu L, Nelson K. The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion 2010;50:1505-11. [PMID: 20456675 DOI: 10.1111/j.1537-2995.2010.02616.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]